Personalizing progressive changes to brain structure in Alzheimer's disease using normative modeling
Neuroanatomical normative modeling was applied to serial Alzheimer's disease (AD) magnetic resonance imaging (MRI) data for the first time. Deviation from the norm (outliers) of cortical thickness or brain volume was computed in 3233 scans. The number of brain-structure outliers increased over time in people with AD. Patterns of change in outliers varied markedly between individual patients with AD. People with mild cognitive impairment whose outliers increased over time had a higher risk of progression from AD.
Authors
- James H. Cole (ORCID: https://orcid.org/0000-0003-1908-5588)
- Duygu Tosun (ORCID: https://orcid.org/0000-0001-8644-7724)
- Serena Verdi (ORCID: https://orcid.org/0000-0002-2421-4818)
- Saige Rutherford (ORCID: https://orcid.org/0000-0003-3006-9044)
- André F. Marquand (ORCID: https://orcid.org/0000-0001-5903-203X)
- André Altmann (ORCID: https://orcid.org/0000-0002-9265-2393)
- Charlotte Fraza (ORCID: https://orcid.org/0000-0002-7088-9250)
- Lars Lau Raket
- Jonathan M. Schott (ORCID: https://orcid.org/0000-0003-1422-4358)
Institutions
- Radboud University Nijmegen (NL)
- University of California, San Francisco (US)
- Lund University (SE)
- Radboud University Medical Center (NL)
- University of California System (US)
- UK Dementia Research Institute (GB)
- National Hospital for Neurology and Neurosurgery (GB)
- University College London (GB)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2024-09-05
- DOI
- https://doi.org/10.1002/alz.14174
- Citations
- 27
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 10.41
Funders
- U.S. Department of Defense
- Foundation for the National Institutes of Health
- Alzheimer's Association
- Bristol-Myers Squibb
- Alzheimer's Drug Discovery Foundation
- Eli Lilly and Company
- Pfizer
- Biogen
- University of Southern California
- AbbVie
- F. Hoffmann-La Roche
- Alzheimer's Disease Neuroimaging Initiative
- BioClinica
- Novartis Pharmaceuticals Corporation
- Takeda Pharmaceutical Company
- Northern California Institute for Research and Education
- Weston Brain Institute
- EU Joint Programme – Neurodegenerative Disease Research
- Brain Research UK
- National Institute for Health and Care Research
- British Heart Foundation
- University College London
- Agence Nationale de la Recherche
- ZonMw
- Ministero della Salute
- Fujirebio Europe
- Servier
- H. Lundbeck A/S
- National Institutes of Health
- Genentech
- GE Healthcare
- Canadian Institutes of Health Research
- Medical Research Council
- Engineering and Physical Sciences Research Council
- Eisai Incorporated
- UCLH Biomedical Research Centre
- National Research, Development and Innovation Office
- National Institute on Aging
- National Institute of Biomedical Imaging and Bioengineering